CN105228623A - 治疗b2-缓激肽受体介导的血管性水肿的方法 - Google Patents

治疗b2-缓激肽受体介导的血管性水肿的方法 Download PDF

Info

Publication number
CN105228623A
CN105228623A CN201480027533.7A CN201480027533A CN105228623A CN 105228623 A CN105228623 A CN 105228623A CN 201480027533 A CN201480027533 A CN 201480027533A CN 105228623 A CN105228623 A CN 105228623A
Authority
CN
China
Prior art keywords
base
methyl
chloro
phenyl
methylquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480027533.7A
Other languages
English (en)
Chinese (zh)
Inventor
K·利奇
T·莱特
B·菲利斯
R·菲佛
P·加莱斯
T·麦考利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of CN105228623A publication Critical patent/CN105228623A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201480027533.7A 2013-03-14 2014-03-12 治疗b2-缓激肽受体介导的血管性水肿的方法 Pending CN105228623A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786126P 2013-03-14 2013-03-14
US61/786126 2013-03-14
PCT/US2014/024540 WO2014159637A1 (en) 2013-03-14 2014-03-12 Methods of treating b2-bradykinin receptor mediated angioedema

Publications (1)

Publication Number Publication Date
CN105228623A true CN105228623A (zh) 2016-01-06

Family

ID=51625217

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027533.7A Pending CN105228623A (zh) 2013-03-14 2014-03-12 治疗b2-缓激肽受体介导的血管性水肿的方法

Country Status (12)

Country Link
US (1) US20160030416A1 (https=)
EP (1) EP2968308A4 (https=)
JP (1) JP2016514141A (https=)
KR (1) KR20150127718A (https=)
CN (1) CN105228623A (https=)
AU (1) AU2014244592A1 (https=)
BR (1) BR112015022846A2 (https=)
CA (1) CA2904052A1 (https=)
HK (1) HK1220136A1 (https=)
MX (1) MX2015012650A (https=)
RU (1) RU2015138443A (https=)
WO (1) WO2014159637A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021253523A1 (zh) * 2020-06-15 2021-12-23 泰安市启航生物科技有限公司 合成肽brap及其在制备新冠肺炎抗炎药中的应用
CN113906018A (zh) * 2019-05-23 2022-01-07 法瓦里斯有限责任公司 用于治疗皮肤病的缓激肽（bk）b2受体拮抗剂的1-((s)-1-(3-氯-5-氟-2-((4-(1h-吡唑-1-基)-2-甲基喹啉-8-基氧基)甲基)苯基)乙基)-咪唑啶-2,4-二酮衍生物及其相关化合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017325986B2 (en) * 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
WO2019101906A1 (en) 2017-11-24 2019-05-31 Pharvaris B.V. Novel bradykinin b2 receptor antagonists
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
UY38707A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
RS65427B1 (sr) 2021-08-05 2024-05-31 Pharvaris Gmbh Kompozicija na bazi lipida za oralnu primenu antagonista receptora bradikinina b2
EP4499100A1 (en) 2022-03-25 2025-02-05 Pharvaris GmbH Therapeutic uses of bradykinin b2-receptor antagonists
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
IL315699A (en) 2022-03-25 2024-11-01 Pharvaris Gmbh A solid composition comprising dissolved bradykinin B2 receptor antagonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054038A1 (en) * 2001-06-22 2003-03-20 Crew Marshall D. Pharmaceutical compositions of drugs and neutralized acidic polymers
WO2008067566A1 (en) * 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2008116620A1 (en) * 2007-03-23 2008-10-02 Jerini Ag 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
WO2010003601A1 (en) * 2008-07-11 2010-01-14 Instituto Luso Farmaco D'italia S.P.A. Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
WO2003087090A2 (en) * 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical,Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
EP2316820A1 (en) * 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054038A1 (en) * 2001-06-22 2003-03-20 Crew Marshall D. Pharmaceutical compositions of drugs and neutralized acidic polymers
WO2008067566A1 (en) * 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2008116620A1 (en) * 2007-03-23 2008-10-02 Jerini Ag 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
WO2010003601A1 (en) * 2008-07-11 2010-01-14 Instituto Luso Farmaco D'italia S.P.A. Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRISTOPH GIBSON ET AL: "Novel small molecule bradykinin B2 receptor antagonists", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
SAMADFAM R ET AL: "Contribution of B2 receptors for bradykinin in Arthus reaction-induced plasma extravasation in wild-type or B2 transgenic knockout mice", 《BRITISH JOURNAL OF PHARMACOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113906018A (zh) * 2019-05-23 2022-01-07 法瓦里斯有限责任公司 用于治疗皮肤病的缓激肽（bk）b2受体拮抗剂的1-((s)-1-(3-氯-5-氟-2-((4-(1h-吡唑-1-基)-2-甲基喹啉-8-基氧基)甲基)苯基)乙基)-咪唑啶-2,4-二酮衍生物及其相关化合物
CN113906018B (zh) * 2019-05-23 2024-04-12 法瓦里斯有限责任公司 缓激肽b2受体拮抗剂
WO2021253523A1 (zh) * 2020-06-15 2021-12-23 泰安市启航生物科技有限公司 合成肽brap及其在制备新冠肺炎抗炎药中的应用
US11401303B2 (en) 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof

Also Published As

Publication number Publication date
US20160030416A1 (en) 2016-02-04
EP2968308A1 (en) 2016-01-20
EP2968308A4 (en) 2016-08-24
BR112015022846A2 (pt) 2017-11-07
AU2014244592A1 (en) 2015-09-24
HK1220136A1 (zh) 2017-04-28
CA2904052A1 (en) 2014-10-02
KR20150127718A (ko) 2015-11-17
RU2015138443A3 (https=) 2018-03-15
WO2014159637A1 (en) 2014-10-02
JP2016514141A (ja) 2016-05-19
MX2015012650A (es) 2016-06-21
RU2015138443A (ru) 2017-04-20

Similar Documents

Publication Publication Date Title
CN105228623A (zh) 治疗b2-缓激肽受体介导的血管性水肿的方法
JP6823095B2 (ja) 噴霧乾燥製剤
KR101991326B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
TWI716341B (zh) 使用齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）或其類似物治療和預防內皮功能障礙之方法
CN103038232A (zh) 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
CN104884057B (zh) 大麻素受体介导的化合物
JP2020522569A (ja) 線維症の処置のための組成物
JP2023030022A (ja) 線維症の処置
JPH09506622A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物
WO2019001383A1 (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
JP2022507117A (ja) 呼吸器疾患の処理のための新規な化合物
CA3176909A1 (en) Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
WO2015007073A1 (zh) 奎宁类化合物、其光学异构体及其制备方法和医药用途
JPH09507219A (ja) α−２−アドレノセプター作動剤として有用な７−（２−イミダゾリニルアミノ）キノリン化合物
KR20220008264A (ko) 염증성 장애를 치료하기 위한 화합물 및 방법
US20230159438A1 (en) Arylamides and methods of use thereof
US20220401435A1 (en) Mrgprx2 antagonist for the treatment of pseudo allergic reactions
CN110753688A (zh) 用于治疗呼吸系统疾病的化合物
JP2009511569A (ja) チピファルニブの新規ｉｖ調合物
CN108699043A (zh) 大麻素受体介导化合物
CN101264081B (zh) 治疗肺纤维化的化合物
WO2025256631A1 (zh) 用于治疗过敏性鼻炎的jak抑制剂
US9896415B2 (en) Chalcone derivatives having an anti-allergic activity
CN115803059A (zh) 使用甲基巴多索隆或其类似物治疗covid-19的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160106

WD01 Invention patent application deemed withdrawn after publication